Yao-Li Chen1,2,3, Wei-Chieh Huang4, Hsin-Lei Yao5, Po-Ming Chen4,6, Ping-Yi Lin2, Fu-Yu Feng7, Pei-Yi Chu8,9,10. 1. School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. 2. Department of General Surgery, Changhua Christian Hospital, Changhua, Taiwan, R.O.C. 3. Transplantation Center, Third Xiangya Hospital of Central South University, Changsha, P.R. China. 4. Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan, R.O.C. 5. Research Consultant, Richmond, VA, U.S.A. 6. Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. 7. Department of Medical Imaging, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. fieyel@gmail.com chu.peiy@msa.hinet.net. 8. Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C. fieyel@gmail.com chu.peiy@msa.hinet.net. 9. School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan, R.O.C. 10. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan, R.O.C.
Abstract
BACKGROUND/AIM: RASA1 (p120RasGAP), encodes Ras GTPase-activating protein 1 and, is a potent tumor suppressor gene that is frequently inactivated in several human cancer types. However, its precise role in hepatocellular carcinoma (HCC) has been blurred. MATERIALS AND METHODS: We hypothesized that RASA1 plays a crucial role in tumor pathogenesis and progression of HCC. RASA1 expression levels were analyzed in 226 cases of HCC by immunohistochemistry. RESULTS: It was found that 38.68% (41/106) of the high-grade HCC samples and 54.17% (65/120) of the low-grade HCC samples expressed RASA1 protein. The difference between RASA1 expression in high-grade and low-grade HCC was statistically significant (p=0.02). Additionally, RASA1 high expression was inversely associated with larger tumor size (p<0.001). Although RASA1 is known as a tumor suppressor, its role in overall survival (OS) in HCC is unclear. Kaplan-Meier survival analysis showed that patients with low level of RASA1 expression correlated with a significantly poorer survival compared to those with high level of RASA1 expression. CONCLUSION: These data support that RASA1 could serve as an independent prognostic marker for HCC patients. Copyright
BACKGROUND/AIM: RASA1 (p120RasGAP), encodes Ras GTPase-activating protein 1 and, is a potent tumor suppressor gene that is frequently inactivated in several humancancer types. However, its precise role in hepatocellular carcinoma (HCC) has been blurred. MATERIALS AND METHODS: We hypothesized that RASA1 plays a crucial role in tumor pathogenesis and progression of HCC. RASA1 expression levels were analyzed in 226 cases of HCC by immunohistochemistry. RESULTS: It was found that 38.68% (41/106) of the high-grade HCC samples and 54.17% (65/120) of the low-grade HCC samples expressed RASA1 protein. The difference between RASA1 expression in high-grade and low-grade HCC was statistically significant (p=0.02). Additionally, RASA1 high expression was inversely associated with larger tumor size (p<0.001). Although RASA1 is known as a tumor suppressor, its role in overall survival (OS) in HCC is unclear. Kaplan-Meier survival analysis showed that patients with low level of RASA1 expression correlated with a significantly poorer survival compared to those with high level of RASA1 expression. CONCLUSION: These data support that RASA1 could serve as an independent prognostic marker for HCCpatients. Copyright
Authors: Matthew Breen; Jaime F Modiano; Ingegerd Elvers; Kerstin Lindblad-Toh; Kate Megquier; Jason Turner-Maier; Ross Swofford; Jong-Hyuk Kim; Aaron L Sarver; Chao Wang; Sharadha Sakthikumar; Jeremy Johnson; Michele Koltookian; Mitzi Lewellen; Milcah C Scott; Ashley J Schulte; Luke Borst; Noriko Tonomura; Jessica Alfoldi; Corrie Painter; Rachael Thomas; Elinor K Karlsson Journal: Mol Cancer Res Date: 2019-09-30 Impact factor: 5.852